Upper Git BleedingNCT06996613
Liberal Versus Restrictive Transfusion Strategy in Patients With Upper Git Bleeding
An observational study of Upper Git Bleeding, run by Sohag University at 1 site in Egypt.
Trial summary
Comparison between the effects and results of the two strategies of blood transfusion, liberal and restrictive in patients with upper Git bleeding Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Upper Git Bleeding
- What is being tested?
- Upper endoscopy
- Type of treatment
- Surgery or procedure
- How many people
- 200 participants
- Where
- 1 siteEgypt
- Study dates
- 22 May 2025to 30 Nov 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with upper Git bleeding in sohag university hospital
Who may be able to join
- all patients presented by upper GIT bleeding and their CBC show anemia and need blood transfusion
Who cannot join
- all patients less than 18 years and patients have anemia and received blood transfusion by another causes other than GIT bleeding
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Faculty of medicine sohag university
Sohag
Reham Elsayed, 01148187498, reham-elsayed-post@med.sohag.edu.eg
Reham Elsayed
About this study
Official title: Liberal Versus Restrictive Transfusion Strategy in Patients With Upper Git Bleeding in Sohag University Hospital
Comparison between the effects and results of the two strategies of blood transfusion, liberal and restrictive in patients with upper Git bleeding
Read the detailed description
Comparison between safety, efficacy and mortality rate in the two strategies of blood transfusion, liberal(target Hb 9-11g/dl) and restrictive(target Hb 7-9 g/dl )in patients with upper Git bleeding in sohag university hospital, and how other risk factors as liver cirrhosis , CKD,and cause of bleeding in the patient affect results and expected complications that may be occur after blood transfusion
- Conditions
- Upper Git Bleeding
- Being tested
- Upper endoscopy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Upper endoscopyProcedure or surgery
It's a diagnostic endoscope to show the cause of upper Git bleeding
What is being measured
The primary outcome is the main question the study is designed to answer.
the rate of complication of both liberal and restrictive transfusion strategy in upper Git bleeding
To assess outcomes and any unwanted complications of both liberal and restrictive transfusion strategy in patients with upper GIT bleeding after reaching target Hb
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 May 2025
- Study start22 May 2025 (estimated)
- Primary completion30 Oct 2025 (estimated)
- Study completion30 Nov 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Upper Git BleedingStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Reham Elsayed Ibrahim, Sohag University
- Investigators
- Reham Elsayed, Study chair, Sohg university hospitalReham Elsayed, Principal investigator, Tertiary hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06996613
- Sponsor's protocol ID
- Soh-Med--25-5-12MS
- Status last verified
- May 2025
- First submitted
- 21 May 2025
- Last updated
- 30 May 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Risk of re identification of participant data and privacy concerns * Reuse of data for proposes that had not been approved by participants * Reuse of data for unfair commercial proposes
Study at a glance
From the registry record, last updated by the sponsor on 30 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Liberal Versus Restrictive Transfusion Strategy in Patients With Upper Git Bleeding in Sohag University Hospital
- ClinicalTrials.gov ID
- NCT06996613
- Acronym / sponsor ID
- Soh-Med--25-5-12MS
- Conditions
- Upper Git Bleeding
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 22 May 2025 (estimated)
- Primary completion
- 30 Oct 2025 (estimated)
- Study completion
- 30 Nov 2025 (estimated)
- First posted
- 30 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Comparison between the effects and results of the two strategies of blood transfusion, liberal and restrictive in patients with upper Git bleeding
Detailed description
Comparison between safety, efficacy and mortality rate in the two strategies of blood transfusion, liberal(target Hb 9-11g/dl) and restrictive(target Hb 7-9 g/dl )in patients with upper Git bleeding in sohag university hospital, and how other risk factors as liver cirrhosis , CKD,and cause of bleeding in the patient affect results and expected complications that may be occur after blood transfusion
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with upper Git bleeding in sohag university hospital
Key inclusion criteria (1 listed)
- all patients presented by upper GIT bleeding and their CBC show anemia and need blood transfusion
Key exclusion criteria (1 listed)
- all patients less than 18 years and patients have anemia and received blood transfusion by another causes other than GIT bleeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Upper endoscopyIt's a diagnostic endoscope to show the cause of upper Git bleeding | Procedure or surgery | – |
Primary outcome
the rate of complication of both liberal and restrictive transfusion strategy in upper Git bleeding
Time frame: Baseline
To assess outcomes and any unwanted complications of both liberal and restrictive transfusion strategy in patients with upper GIT bleeding after reaching target Hb
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 May 2025.
- Individual participant dataSharing planned: Undecided. Risk of re identification of participant data and privacy concerns * Reuse of data for proposes that had not been approved by participants * Reuse of data for unfair commercial proposes
Related trials for Upper Git Bleeding
Active, not recruitingObservational study
Impact of Diagnostic and Therapeutic Upper and Lower Gastrointestinal Endoscopic Management on Critically Ill Patients in Fayoum University Hospitals
GIT Bleeding
Not yet recruitingObservational study
HALP as a Novel Score for Prediction of Mortality and re_bleeding in Upper GIT Bleeding
Upper Gastrointestinal Bleeding
Not yet recruitingObservational study
Endoscopic Findings in Patients With Upper GIT Bleeding
GIT - Gastrointestinal Tract Hemorrhage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Reham Elsayed study chair
Sohg university hospital
Reham Elsayed principal investigator
Tertiary hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Upper Git Bleeding, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 30 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Reham Elsayed (01148187498, reham-elsayed-post@med.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the rate of complication of both liberal and restrictive transfusion strategy in upper Git bleeding (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 May 2025.